<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Ophthalmology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0301-4738</issn>
      <issn pub-type="epub">1998-3689</issn>
      <publisher>
        <publisher-name>Medknow Publications</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18417831</article-id>
      <article-id pub-id-type="pmc">2636104</article-id>
      <article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_3_243_40369</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Voriconazole for the treatment of refractory <italic> Aspergillus fumigatus</italic>  keratitis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Mehta</surname>
            <given-names>Hijab</given-names>
          </name>
          <degrees>MS</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mehta</surname>
            <given-names>Hitendra B</given-names>
          </name>
          <degrees>MS</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garg</surname>
            <given-names>Prashant</given-names>
          </name>
          <degrees>MS</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kodial</surname>
            <given-names>Harish</given-names>
          </name>
          <degrees>MS</degrees>
        </contrib>
      </contrib-group>
      <aff>Infiniti Eye Hospital (HM, HBM), Jaya Mahal, French Bridge, Opera
House, Mumbai - 400 007, Maharashtra; LV Prasad Eye Institute (PG),
Banjara Hills, Hyderabad - 500 034, Andhra Pradesh; Cumballa Hill
Hospital (HK), Kemps Corner, Mumbai - 400 036, Maharashtra, India
</aff>
      <author-notes>
        <corresp id="cor1">Correspondence to Dr. H?ab Mehta, Infiniti Eye Hospital, 6, Jaya
Mahal, Next to Patidar Samaj Hall, French Bridge, Opera House,
Mumbai - 400 007, Maharashtra, India. Email:<email>drhijabmehta@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2008</year>
      </pub-date>
      <volume>56</volume>
      <issue>3</issue>
      <fpage>243</fpage>
      <lpage>245</lpage>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>6</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>8</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Ophthalmology</copyright-statement>
        <copyright-year>2008</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an 
open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly 
cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We report a case of <italic>Aspergillus fumigatus</italic> keratitis in a 53-year-old,
well-controlled diabetic female who did not respond to standard
antifungal treatment. She was started on topical natamycin
eye drops, but the infiltrate continued to progress. Topical
amphotericin B and systemic ketoconazole was added, however,
there was no response and the infiltrate increased further. She
was then switched to topical and systemic voriconazole. Steady
resolution of the infiltrate was noted within 2 weeks of therapy.</p>
      </abstract>
      <kwd-group>
        <kwd>
          <italic>Aspergillus</italic>
        </kwd>
        <kwd>fungal keratitis</kwd>
        <kwd>voriconazole</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Fungal keratitis is a leading cause of ocular morbidity; one
report from South India found that 44% of all central corneal
ulcers are caused by fungi.<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref2">2</xref> Isolated pathogens vary
with the geographic area studied.<xref ref-type="bibr" rid="ref3">3</xref> Yeast, especially <italic>Candida</italic> predominate
in the temperate regions, whereas tropical isolates are mostly
filamentous fungi. In India, filamentous fungi are the major
etiologic agents of fungal keratitis. <italic>Fusarium</italic> and <italic>Aspergillus</italic>
species are the most commonly implicated pathogens.<xref ref-type="bibr" rid="ref2">2</xref>-<xref ref-type="bibr" rid="ref5">5</xref></p>
    <p>Therapy of fungal infections, both ocular and systemic, can be
difficult and prolonged. Challenges include limited number of
antifungal agents, fungistatic nature of the available antifungals
and poor tissue penetration of previously investigated agents.
Voriconazole (Vfend; Pfizer Pharmaceuticals) is a new triazole
antifungal agent, with the broadest spectrum of antifungal
activity.<xref ref-type="bibr" rid="ref6">6</xref>-<xref ref-type="bibr" rid="ref10">10</xref> The purpose of this case is to report
that voriconazole has worked effectively in a patient with <italic>Aspergillus fumigatus</italic>
keratitis, which did not respond to standard antifungal
therapy.</p>
    <sec sec-type="">
      <title>Case Report</title>
      <p>A 53-year-old female came to us with history of foreign
body entry in the left eye. Renovation of her house was
underway and the exact nature of the foreign body was not
known to her; however, she washed her eyes with plenty of
tap water to get rid of it. She presented to us the next day
with a large central corneal epithelial defect 7 mm &#xD7; 6 mm
in size, there was no infiltrate, there were two old corneal
scars in the midperipheral cornea, she was treated with
topical gatifloxacin and homatropine. The epithelial defect
reduced, she was symptomatically better on the following
day; however, on the third day, she developed a superficial
corneal infiltrate with hyphate edges 2 mm &#xD7; 1 mm and a
satellite lesion [<xref ref-type="fig" rid="F1">Fig. 1</xref>], visual acuity was 20/40, clinically it
appeared to be a fungal infection. Our patient was a family
physician herself and was explained the need for a corneal
scraping [<xref ref-type="fig" rid="F2">Fig. 2</xref>]; she insisted that we give empirical treatment
with an antifungal medication and scrape only, if there was
no response. She was treated with 5% natamycin eye drops
half hourly along with homatropine eye drops thrice a day
and gatifloxacin eye drops four times a day, also epithelial
debridement was done regularly in view of poor corneal
penetration of topical antifungal agents. After showing an
initial response to the treatment [<xref ref-type="fig" rid="F3">Fig. 3</xref>], the infiltrate increased
in size and density, corneal scraping revealed filamentous
fungus, cultures grew <italic>Aspergillus fumigatus</italic> [<xref ref-type="fig" rid="F4">Fig. 4</xref>]. Since she
had worsened despite 2 weeks of natamycin, we added topical
amphotericin B 0.15% and systemic ketoconazole 200 mg
twice a day. She gave history of diabetes since 3 years, which
was well controlled, liver functions and renal functions were
within the normal range and she had no history of any other
systemic illness. Since the infiltrate kept increasing even with
combined natamycin and amphotericin B therapy over the
next 10 days [<xref ref-type="fig" rid="F5">Fig. 5</xref>], we started her on topical voriconazole
1% every hour and systemic voriconazole 400 mg twice a
day was given as loading dose on the first day followed by
200 mg twice a day. There was a steady resolution of the
infiltrate in 2 weeks; topical voriconazole was tapered slowly
over 2 months; oral therapy was discontinued by the end of
3 months, when the lesion scarred completely [<xref ref-type="fig" rid="F6">Fig. 6</xref>] and
vision was 2/60. There were no adverse events other than mild
photosensitivity; liver function tests were repeated every 4
weeks and remained normal.</p>
    </sec>
    <sec sec-type="">
      <title>Discussion</title>
      <p><italic>Aspergillus</italic> is a filamentous and ubiquitous fungus found in
nature, commonly isolated from soil, plant debris and indoor
air environment. It is known to cause opportunistic infections,
especially in immunosuppressed individuals. Any organ
system in the body may be involved. As with other filamentous
fungi, most cases of <italic>Aspergillus</italic> keratitis have a history of
trauma, particularly with vegetable matter.<xref ref-type="bibr" rid="ref2">2</xref>-<xref ref-type="bibr" rid="ref5">5</xref></p>
      <p>Voriconazole is a triazole antifungal agent and is a second-
generation synthetic derivative of fluconazole; it is effective
against yeast and filamentous fungi. The primary mode of
action of voriconazole is the inhibition of cytochrome P-450-
mediated 14-&#x3B1;-lanosterol demethylation, an essential step in
fungal ergosterol biosynthesis and the resulting ergosterol
depletion causes fungal cell wall destruction. It is well tolerated
after oral administration; therapeutic aqueous and vitreous
levels are achieved after administration of upto 200 mg twice
a day.<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></p>
      <p>Reports of topical and oral voriconazole have illustrated
its efficacy in the management of fungal keratitis caused by
<italic>Candida, Fusarium, Alternaria, Scedosporium</italic> that was refractory
to standard antifungal agents but responded to voriconazole
treatment.<xref ref-type="bibr" rid="ref11">11</xref> It has also been effective for the treatment of
<italic>Aspergillus fumigatus</italic> scleritis and epibulbar abscess resulting
from scleral buckle infection.<xref ref-type="bibr" rid="ref6">6</xref> Intravitreal voriconazole has
been used for drug-resistant fungal endophthalmitis.<xref ref-type="bibr" rid="ref13">13</xref> A recent
report has compared the minimum inhibitory concentration
(MIC) of natamycin, amphotericin, and voriconazole against
<italic>Aspergillus</italic> species isolated from keratitis.<xref ref-type="bibr" rid="ref14">14</xref> MIC of natamycin
was 32 &#xB5;g/ml, MIC of amphotericin B was 2-4 &#xB5;g/ml, and
that of voriconazole was the lowest 0.25-0.5 &#xB5;g/ml. It is to be
noted that effectiveness of antifungal agents depends on the
concentration of drug achieved locally; in practice, the topical
antifungals are given at different concentrations - amphotericin
B because of toxicity is prescribed at 0.15%, voriconazole at
1% and natamycin at 5%; thus, although the MIC level of
natamycin is higher, it is administered at five times the strength
of voriconazole and 30 times that of amphotericin B. Thus, the
natamycin MIC would need to be adjusted according to the
available dose and will be lower.</p>
      <p>Based on the available literature, eye drops were prepared
by reconstituting lyophilized powder used for parenteral
administration (Vfend 200 mg, Pfizer) with 19-ml sterile
water for injection to obtain 20 ml of 1% solution and were
administered every hour round the clock initially, they
were then gradually tapered as the infection resolved over
2 months. The corneal infiltrate reduced remarkably in 2 weeks;
however, the endothelial exudates and hypopyon took nearly
10 weeks to settle. Voriconazole eye drops were prepared every
alternate day, stability of the solution could be extended up to
48 h between 2&#xB0;C and 8&#xB0;C, according to the manufacturer.<xref ref-type="bibr" rid="ref11">11</xref>
Epithelial debridement may not be necessary for voriconazole
penetration, because voriconazole is a small, lipophilic
molecule.<xref ref-type="bibr" rid="ref12">12</xref> For optimum intraocular drug concentration,
both oral and topical administration of voriconazole is
recommended.<xref ref-type="bibr" rid="ref12">12</xref> Adverse effects of systemic use include
visual disturbances such as enhanced light perception, color
vision changes, visual blurring, skin rash, and hepatotoxicity,
which are all transient in nature; on topical application, ocular
burning has been reported. The duration of treatment depends
on severity of keratitis and individual clinical response; it has
been used for upto 4 months.<xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref11">11</xref></p>
      <p>Because of its broad spectrum of coverage, good tolerability,
and excellent bioavailability with oral administration,
voriconazole may be a good alternative against fungi-resistant
to standard antifungal agents; however, the expenditure
involved in voriconazole treatment will pose a constraint in
its more frequent usage.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>Dr. Camila Rodrigues, Microbiology Department, P.D. Hinduja
National Hospital and Medical Research Centre, Mahim,
Mumbai, for laboratory diagnosis of fungal infection.</p>
    </ack>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharma</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Srinivasan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>The current status of Fusarium
species in mycotic keratitis in South India</article-title>
          <source>J Med Microbiol</source>
          <year>1993</year>
          <volume>11</volume>
          <fpage>140</fpage>
          <lpage>7</lpage>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Srinivasan</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Fungal keratitis</article-title>
          <source>Curr Opin Ophthalmol</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>321</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">15232472</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garg</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gopinathan</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Choudhary</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>GN</given-names>
            </name>
          </person-group>
          <article-title>Keratomycosis:
Clinical and microbiologic experience with dematiaceous fungi</article-title>
          <source>Ophthalmology</source>
          <year>2000</year>
          <volume>107</volume>
          <fpage>574</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">10711898</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bharathi</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Ramakrishnan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Vasu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Meenakshi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Palaniappan</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Epidemiological characteristics and laboratory diagnosis of fungal keratitis: A three-year study</article-title>
          <source>Indian J Ophthalmol</source>
          <year>2003</year>
          <volume>51</volume>
          <fpage>315</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="pmid">14750619</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gopinathan</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fernandes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Atmanathan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>GN</given-names>
            </name>
          </person-group>
          <article-title>The epidemiologic features and laboratory results of fungal
keratitis: A 10 year review at a referral eye care centre in South
India</article-title>
          <source>Cornea</source>
          <year>2002</year>
          <volume>21</volume>
          <fpage>555</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">12131029</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Perkins</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Voriconazole treatment for fungal
scleritis and epibulbar abcess resulting from scleral buckle
infection</article-title>
          <source>Arch Ophthalmol</source>
          <year>2003</year>
          <volume>121</volume>
          <fpage>735</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">12742860</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Denning</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Ribaud</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Milpied</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Caillot</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Herbrecht</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Thiel</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy and safety of voriconazole in the treatment of acute
invasive aspergillosis</article-title>
          <source>Clin Infect Dis</source>
          <year>2002</year>
          <volume>34</volume>
          <fpage>563</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="pmid">11807679</pub-id>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sundmacher</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tintelnot</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Agostini</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Althaus</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Successful treatment of ocular invasive mold infection
(fusariosis) with the new antifungal agent voriconazole</article-title>
          <source>Br J Ophthalmol</source>
          <year>2000</year>
          <volume>84</volume>
          <fpage>932</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">10979655</pub-id>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hariprasad</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Meiler</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Holz</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Chi</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Determination of vitreous, aqueous and plasma concentration of
orally administered voriconazole in humans</article-title>
          <source>Arch Ophthalmol</source>
          <year>2004</year>
          <volume>122</volume>
          <fpage>42</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">14718293</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marangon</surname>
              <given-names>FB</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Giaconi</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Alfonso</surname>
              <given-names>EC</given-names>
            </name>
          </person-group>
          <article-title><italic>In vitro</italic> investigation
of voriconazole susceptibility for keratitis and endophthalmitis
fungal pathogens</article-title>
          <source>Am J Ophthalmol</source>
          <year>2004</year>
          <volume>137</volume>
          <fpage>820</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">15126145</pub-id>
        </element-citation>
      </ref>
      <ref id="ref11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bunya</surname>
              <given-names>VY</given-names>
            </name>
            <name>
              <surname>Hammersmith</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Rapuano</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Brandon</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Elisabeth</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Topical and oral Voriconazole in the treatment of fungal
keratitis</article-title>
          <source>Am J Ophthalmol</source>
          <year>2007</year>
          <volume>143</volume>
          <fpage>151</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">17188052</pub-id>
        </element-citation>
      </ref>
      <ref id="ref12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thiel</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Zinkernagel</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Burhenne</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Haefeli</surname>
              <given-names>WE</given-names>
            </name>
          </person-group>
          <article-title>Voriconazole concentration in human aqueous humor and
plasma during topical or combined topical and systemic
administration for fungal keratitis</article-title>
          <source>Antimicrobial Agents
Chemother</source>
          <year>2007</year>
          <volume>51</volume>
          <fpage>239</fpage>
          <lpage>44</lpage>
        </element-citation>
      </ref>
      <ref id="ref13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gopal</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sen</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
          <article-title>Intravitreal Voriconazole for drug resistant
fungal endophthalmitis: Case series</article-title>
          <source>Retina</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>935</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">17031296</pub-id>
        </element-citation>
      </ref>
      <ref id="ref14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laitha</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Srinivasan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Prajna</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Acharya</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Fothergill</surname>
              <given-names>AW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antimicrobial susceptibility of fusarium,
aspergillus and other filamentary fungi isolated from keratitis</article-title>
          <source>Arch Ophthalmol</source>
          <year>2007</year>
          <volume>125</volume>
          <fpage>789</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="pmid">17562990</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Central infiltrate with hyphate edges, two old scars towards
11 o'clock and 5 o'clock</p>
      </caption>
      <alt-text>Figure 1</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-243-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Increase in the infiltrate size and density, necessitated
scraping</p>
      </caption>
      <alt-text>Figure 2</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-243-g002"/>
    </fig>
    <fig id="F3" position="float">
      <label>Figure 3</label>
      <caption>
        <p>On day 7 of natamycin eye drops, initial response to empiric
treatment seen, natamycin precipitate present on the ulcer bed</p>
      </caption>
      <alt-text>Figure 3</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-243-g003"/>
    </fig>
    <fig id="F4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Day 14 of natamycin eye drops worsening of infection, corneal
scraping reveals fungal filaments</p>
      </caption>
      <alt-text>Figure 4</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-243-g004"/>
    </fig>
    <fig id="F5" position="float">
      <label>Figure 5</label>
      <caption>
        <p>Day 27 of natamycin and day 11 of amphotericin, progression
of the infiltrate despite the combination, voriconazole started</p>
      </caption>
      <alt-text>Figure 5</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-243-g005"/>
    </fig>
    <fig id="F6" position="float">
      <label>Figure 6</label>
      <caption>
        <p>After 3 months of voriconazole treatment, central corneal
scar</p>
      </caption>
      <alt-text>Figure 6</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-243-g006"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
